Verve Therapeutics (VERV)
(Delayed Data from NSDQ)
$6.28 USD
+0.61 (10.76%)
Updated Jul 9, 2024 04:00 PM ET
After-Market: $6.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for Verve Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 12 | 2 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 12 | 2 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 235 | 168 | 87 | 41 | 14 |
Income After Depreciation & Amortization | -223 | -166 | -87 | -41 | -14 |
Non-Operating Income | 23 | 8 | -33 | -5 | -6 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -200 | -157 | -120 | -46 | -19 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -200 | -157 | -120 | -46 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -200 | -157 | -120 | -46 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -232 | -164 | -84 | -39 | -14 |
Depreciation & Amortization (Cash Flow) | -9 | 2 | 3 | 2 | 0 |
Income After Depreciation & Amortization | -223 | -166 | -87 | -41 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 64.18 | 54.02 | 26.87 | NA | NA |
Diluted EPS Before Non-Recurring Items | -3.12 | -2.91 | -4.48 | NA | NA |
Diluted Net EPS (GAAP) | -3.12 | -2.91 | -4.48 | NA | NA |
Fiscal Year end for Verve Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 5.70 | 5.14 | 3.12 | 2.09 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 5.70 | 5.14 | 3.12 | 2.09 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 62.54 | 59.09 | 55.46 | 60.68 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -56.84 | -53.95 | -52.34 | -58.59 |
Non-Operating Income | NA | 8.21 | 5.63 | 6.64 | 4.78 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -48.63 | -48.32 | -45.69 | -53.81 |
Income Taxes | NA | 0.11 | 0.03 | 0.07 | 0.18 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -48.74 | -48.35 | -45.76 | -53.98 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -48.74 | -48.35 | -45.76 | -53.98 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 83.13 | 69.67 | 63.21 | 61.95 |
Diluted EPS Before Non-Recurring Items | NA | -0.59 | -0.69 | -0.72 | -0.87 |
Diluted Net EPS (GAAP) | NA | -0.59 | -0.69 | -0.72 | -0.87 |